CI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cigna Group (CI) is not a strong buy at this moment for a beginner investor with a long-term focus. While the stock has positive long-term catalysts such as analyst upgrades and strategic initiatives, the recent financial performance and technical indicators suggest a cautious approach. The lack of strong trading signals and the potential for near-term price declines further support a hold recommendation.
The technical indicators show mixed signals. The MACD is positive and expanding, suggesting bullish momentum, but the RSI is neutral at 65.089. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downtrend. Key resistance levels are at 271.454 and 274.784, while support levels are at 260.674 and 257.344. The stock is trading near resistance, limiting immediate upside potential.
Analyst upgrades with increased price targets, including Bernstein's upgrade to Outperform with a $358 target.
Strategic initiatives such as the PBM reform and FTC settlement, which are expected to drive long-term growth.
Positive social impact initiatives, such as the $3 million investment to support veterans' housing and mental health.
Weak Q4 financial performance, with net income dropping by -13.34% YoY and EPS declining by -11.31% YoY.
Bearish moving averages and a potential near-term price decline based on candlestick pattern analysis.
Broader market weakness, as indicated by the S&P 500's -1.79% change.
In Q4 2025, revenue increased by 10.39% YoY to $72.47 billion, but net income dropped by -13.34% YoY to $1.23 billion. EPS declined by -11.31% YoY to $4.55, and gross margin fell by -10.65% YoY to 8.22%. The financial performance shows growth in revenue but declining profitability metrics.
Analysts are broadly positive on Cigna, with several upgrades and increased price targets. Bernstein upgraded the stock to Outperform with a $358 target, citing clearing events and long-term growth potential. Piper Sandler, Truist, and UBS also raised their price targets, reflecting confidence in the company's strategic initiatives. However, Barclays and Cantor Fitzgerald highlighted potential risks related to Medicare Advantage rates and political influences.
